Globus Medical Inc. (NYSE:GMED) is one of the best medical technology stocks to invest in. On January 30, Needham upgraded its rating on Globus Medical Inc. (NYSE:GMED) from Hold to Buy and set the ...

Globus Medical (GMED) has seen mixed share performance recently, with a roughly 4% decline over the past month and a 5% decline over the past week, while the past 3 months show a 41% gain. See our ...

Globus Medical is rated Hold, as growth is increasingly reliant on M&A and organic momentum remains muted. GMED's FY26 guidance implies 9% revenue growth, a sharp deceleration from FY25's 16.5%, with ...

Globus Medical has provided preliminary fourth-quarter 2025 financial results. The company forecasts a more robust bottom line in 2026 than what analysts anticipate. Shares of Globus Medical are ...

Weekly news magazine known for its willingness to tackle sensitive issues in Croatian society and resist government pressure printed its final edition on Wednesday. A ‘Globus’ reader in Zagreb, April ...

Alzheimer’s disease is one of humanity’s most formidable foes. It affects 10 percent of people over age 65 and kills more people each year than breast cancer and prostate cancer combined. Its effects ...

Infinity Globus provides outsourced tax and accounting services. Smart Accountants provides international tax and business formation services for businesses. Together, they add 191 employees to ...

Here’s why we believe Globus Medical (GMED) stock merits attention as a value stock. It’s currently trading approximately 33% below its 1-year high and is also trading at a PS multiple that falls ...

Victor Sung, M.D., director of the Division of Movement Disorders in the University of Alabama at Birmingham Department of Neurology and director of the UAB Huntington’s Disease Clinic, reacted to the ...

Every week neurologist Victor Sung sees people with Huntington’s disease, a rare and deadly neurodegenerative disorder, at his clinic at the University of Alabama at Birmingham. But a Wednesday in ...